Browse Articles

Discover research articles across all indexed journals

Modified transurethral resection of bladder tumors: A comparison study of chemotherapy-enhanced endoscopic submucosal en bloc dissection versus conventional resection.

Journal of Clinical Oncology Xi Liu, Yiding Wang, Zhe Wang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.721

721 Background: High recurrence rates plague patients with nonmuscle invasive bladder cancer (NMIBC) following transurethral resection of bladder tumors (TURBT). In response, we have developed a modified TURBT procedure that integrates en bloc resection, endoscopic submucosal dissection, and the injection of chemotherapeutic drugs into the submucosa (cESD-TURBT).This study aims to determine if cESD-TURBT yields better outcomes than conventional TURBT (cTURBT). Methods: This retrospective observational study was conducted on patients diagnosed with cTa–T1 bladder cancer who received TURBT between December 2020 and July 2023 in Liaoning Cancer Hospital. Participants were grouped based on the type of treatment they received: cESD-TURBT (n=118) or conventional TURBT (cTURBT, n=105). Hydroxycamptothecin was the chemotherapeutic agent used for submucosal injections. The primary outcome was recurrence-free survival (RFS) of the treated bladder cancer. Secondary outcomes included disease recurrence within one year, operation duration, length of postoperative hospitalization, and complication rates. Statistical analyses were performed using appropriate tests, with a threshold of P < 0.05 defined as statistically significant. Results: Among the 223 patients, cESD-TURBT cohort demonstrated enhanced RFS compared to cTURBT cohort, with a median follow-up of 775 days (IQR 414-1040). The recurrence rate in the cESD-TURBT cohort was 18.64% (22/118), against 39.05% (41/105) in the cTURBT cohort, with a log-rank hazard ratio of 0.49 (95% CI 0.29-0.82; p=0.0053). Furthermore, cESD-TURBT registered fewer postoperative complications than cTURBT, markedly reducing occurrences such as the obturator reflex (2% vs. 9%). The difference in operation times was not statistically significant, with cESD-TURBT averaging 49.0 ± 21.0 minutes and cTURBT 44.3 ± 23.8 minutes, the difference being statistically negligible (p=0.127). Conclusions: For patients with NMIBC, cESD-TURBT significantly lowers recurrence rates compared to cTURBT and is associated with fewer postoperative complications. Our study reveals that the chemotherapy-enhanced ESD-TURBT technique significantly improves recurrence-free survival and reduces complications, making it a superior method over conventional TURBT for bladder tumor removal.

PSA-based intermediate endpoints to compare radiotherapy and radical prostatectomy for the treatment of localized prostate cancer.

Journal of Clinical Oncology Ugo Giovanni Falagario, Francesco Pellegrino, Giuseppe Carrieri et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.366

366 Background: There is no validated PSA-based endpoint to compare oncological outcomes after radical prostatectomy (RP) and radiation therapy (RT). We aimed to define a novel PSA-based intermediate endpoint that leads to similar prostate cancer-specific mortality (PCSM) for primary treatment comparison. Methods: This population-based study included all men with cT1-3, cN0M0 prostate cancer (PCa) in Stockholm who underwent RP or RT with PSA follow-up from 2003 to 2021. Competing risk regression, accounting for non-PCa mortality, was used to compare the cumulative incidence of PCSM in patients meeting different PSA-based endpoints after RP and RT. Endpoints were predefined by systematically increasing PSA cut-offs and PSA doubling times (PSA-DT) at recurrence. The analysis was adjusted for age at diagnosis, Charlson, PSA, ISUP Gleason at biopsy, cT stage, and treatment year, and was repeated to identify endpoint combinations that resulted in similar PCSM for RT and RP (subdistribution hazard ratio [SHR] of RT vs RP close to 1). Results: 12,010 (67.7%) man underwent RP, and 5,743 (32.3%) underwent RT. The median follow-up for survivors was 91 months (IQR 70–154) after treatment. A total of 428 men died from PCa. The adjusted SHR for patients meeting the current definition of biochemical recurrence (BCR) after RT (PSA ≥ nadir + 2) was 3.35 (95% CI 2.67, 4.23) compared to RP patients with a rising PSA≥0.2. Similar results were found when comparing PSA nadir + 2 with patients reaching higher PSA cut-offs after RP (≥ 0.5 and ≥ 1 ng/ml). Further comparisons were therefore performed by lowering the PSA cut-offs for the RT endpoint (nadir + 1-0.5 ng/ml). The endpoint definition leading to similar survival rates was PSA nadir + 0.5 ng/ml after RT and PSA ≥ 0.5 ng/ml with PSA DT < 9 months after RP (SHR RT vs RP 1.00, 95% CI 0.78, 1.29). The adjusted cumulative incidence of the endpoint was higher after RT. Conclusions: We performed a systematic analysis of PSA-based early endpoints following primary treatment for PCa and found that patients who underwent RT and reached a PSA ≥ nadir + 0.5 ng/ml had similar survival rates to patients with PSA ≥ 0.5 ng/ml and PSA DT < 9 months after RP. Our results highlight that current BCR definitions are suboptimal for primary treatment comparison and present, for the first time, promising novel early endpoints suitable for further validation. Competing risk regression comparing cumulative incidence of prostate cancer specific mortality after meeting the predefined endpoints after radiotherapy or radical prostatectomy (reference group). Endpoint compared Radical Prostatectomy(reference) Radiotherapy Adjusted SHR for PCa Mortality (RT vs RP) Adjusted Coefficient for PCa Mortality (RT vs RP) SHR 95% CI P Coeff 95% CI P 1 >0.2 nadir+2 ng/ml N of Pt 2501 836 3.35 2.67, 4.23 <0.001 1.21 0.98,1.44 <0.001 2 >0.5 nadir+2 ng/ml N of Pt 1365 836 2.08 1.66, 2.60 <0.001 0.73 0.51,0.96 <0.001 3 >0.5+ DT<12 nadir+2 ng/ml N of Pt 805 836 1.68 1.32, 2.12 <0.001 0.52 0.28,0.75 <0.001 4 >0.5+ DT<9 nadir+2 ng/ml N of Pt 667 836 1.73 1.34, 2.23 <0.001 0.55 0.29,0.80 <0.001 5 >0.5+ DT<9 nadir+1 ng/ml N of Pt 667 1050 1.32 1.03, 1.70 0.030 0.28 0.03,0.53 0.030 6 >0.5+ DT<9 nadir+0.5 ng/ml N of Pt 667 1321 1.00 0.78, 1.29 0.985 0.00 -0.25,0.25 0.985 7 >0.5+ DT<6 nadir+0.5 ng/ml N of Pt 482 1321 0.97 0.74, 1.28 0.853 -0.04 -0.07,-0.00 0.040 Standardized hazard ratios (SHR) are adjusted for age at diagnosis, Charlson comorbidity, PSA, ISUP Gleason at biopsy, clinical Stage, treatment year. SHR: standardized hazard ratios; PCa: Prostate cancer; RP: Radical prostatectomy; RT: radiotherapy; DT: PSA doubling time.

<sup>18</sup> F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing first line tyrosine kinase or checkpoint inhibitor therapy.

Journal of Clinical Oncology Michael D. Staehler, Sophie Kunte, Adrien Holzgreve et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.455

455 Background: Evaluating the effectiveness of systemic therapy in patients with metastatic renal cell carcinoma (mRCC) is crucial for timely treatment adjustments. In an earlier preliminary study on a subset of mRCC patients, we compared responses to systemic therapy using [¹⁸F]PSMA-1007 PET and conventional imaging methods. In this research, our aim was to compare response assessments using PSMA PET versus CT scans in a larger cohort of mRCC patients undergoing systemic therapy. Additionally, we investigated the potential of using PSMA-PET-derived responses to predict outcomes. Methods: We performed a retrospective single-center analysis of patients with mRCC who underwent [¹⁸F]PSMA-1007 PET/CT in the context of tyrosine kinase or checkpoint inhibition and had at least one PET avid metastatic RCC lesion at baseline. All patients were treated with IO combination therapy either in combination with a TKI or ICI. Early treatment response at a mean of 9.5 weeks after the start of systemic therapy was compared to baseline scans. PET responses and measurements were correlated with CT results, progression-free (PFS) and overall survival (OS). Survival data were analyzed using log rank testing and Kaplan-Meier analysis. Results: 25 patients with mRCC were enrolled. Median age was 65.2 years (range 24-87). Median PFS was 16.6 months (range 1.38 -58.69) and median OS 28.8 months (range 3.6 - 65.16). Median SUV, TTV, CT or PET response were not correlated with PFS or OS. Patients with a 10% reduction in SUVmax had a significant longer PFS with 23.1 months (95% CI 13.8-32.3) vs 3.6 (95% CI 1.4 – 5.9) months and OS of 36.2 months (95% CI 17.5 – 70.6) vs 11.1 months (95% CI 5.604 – 16.8) than patients without SUVmax response. SUVmax response was independent of administration of tyrosine kinase inhibitors or checkpoint inhibitors. Conclusions: Reduction of PSMA uptake on PET scans may be an independent biomarker beyond CT findings and warrants further investigation in mRCC. PSMA PET could be used for a better understanding of drug efficacy. Changes in PSMA PET are independent of the mechanism of action of systemic therapy in early prediction of therapy response and therefore might be considered a clinical biomarker.

Identifying priorities and developing collaborative action plans to improve accessible housing practice, policy, and research in Canada

PLoS ONE Sander L. Hitzig, Kirstin E. Yuzwa, Linda Weichel et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0318458

This article describes the development of priorities and actions to improve the state of research, policy, and practice related to accessible housing in Canada for persons with disability or with accessible housing needs. A modified Delphi approach with an expert cross-sectoral panel was used to gain convergence on a set of priorities for advancing the accessible housing field in Canada. This included circulating an anonymous pre-meeting survey (N = 49) followed by an in-person planning meeting (N = 45). The expert panel at the in-person meeting identified three clusters of priorities from an initial list of 21 priorities, which included: 1) engaging with all levels of government to support accessible housing efforts; 2) developing educational resources to raise awareness about accessible housing, and creating services to facilitate locating and acquiring accessible housing; and 3) fostering meaningful engagement across key interest groups and sectors to find solutions to enact positive change in this space. The findings provide an initial roadmap for bringing greater cohesion to the accessible housing field, which will enable cross-sectoral partnerships and collective action towards informing the next generation of accessible housing standards, regulations and practices for people with accessible housing needs.

Decoupling chemical and mechanical signaling in colorectal cancer cell migration

Scientific Reports Maxwell G. Tetrick, Md. Abul Bashar Emon, Umnia Doha et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89152-4

Integrating aggressive variant prostate cancer–associated tumor suppressor genes (AVPC-TSG) status to refine prognosis and predict androgen-receptor pathway inhibitors (ARPI) response in metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology Martino Pedrani, Giuseppe Salfi, Sara Merler et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.243

243 Background: Alterations in AVPC-TSG (TP53, RB1, PTEN) are related with androgen insensitivity and aggressive disease. However, their role in mHSPC prognosis and treatment guidance is unclear. This retrospective study assesses the value of AVPC-TSG alterations in refining prognosis and predicting ARPI benefit in mHSPC. Methods: We included 158 mHSPC patients with available genomic tumor sequencing analysis undergoing treatment between 2013 and 2023. We compared patients with AVPC-TSGalt tumors (defined by ≥1 alterations in the TP53 gene, RB1 gene, or PTEN/PI3K/AKT pathway genes) to those without (AVPC-TSGwt tumors). Cox analyses were performed for progression-free survival (PFS) and overall survival (OS). Results: AVPC-TSGwt status was associated with improved PFS and OS in both univariate and multivariate (MV) analyses (MV PFS: HR 0.58, p=0.012; MV OS: HR 0.48, p=0.025). AVPC-TSGalt mHSPC patients seemed to derive no PFS benefit (PFS: HR 1.13, p=0.721) from the addition of an ARPI to ADT, while AVPC-TSGwt mHSPC patients did (PFS: HR 0.51, p=0.029). Integrating AVPC-TSG status with CHAARTED volume criteria enhanced prognostic and predictive discrimination in mHSPC. Three distinct subgroups were identified: "good-risk" (AVPC-TSGwt and low-volume), "intermediate-risk" (either AVPC-TSGalt or high-volume), and "poor-risk" (AVPC-TSGalt and high-volume) with median PFS of 46.8, 28.2, and 15.7 months, respectively. Among them, only the "intermediate-risk" subgroup seemed to derive PFS benefit (HR 0.36, p=0.002) from addition of an ARPI. Conclusions: Integrating AVPC-TSG status with clinical prognostic variables refines prognostication and may predict PFS benefits from the addition of an ARPI in patients with mHSPC. Patients with AVPC-TSGalt mHSPC should be considered for clinical trials exploring alternative treatments, as they may not benefit from current standard approaches. Patient characteristics. AVPC-TSGaltn=63(39.9%) AVPC-TSGwtn=95(60.1%) p-value mHSPC treatmentADT aloneADT+ARPIADT+DocetaxelADT+ARPI+Docetaxel 23(36.5%)28(44.5%)8(12.7%)4(6.3%) 32(33.6%)49(51.6%)7(7.4%)7(7.4%) p=0.64 1 De Novo disease 43(68.3%) 57 (60%) p=0.29 1 CHAARTED High Volume 36(57.1%) 52(54.7%) p=0.77 1 AVPC-TSG 1 altAVPC-TSG 2-3 alt 56(88.9%)7(11.1%) 00 p&lt;0.012 1 median PFS (months)median OS (months) 20.568.2 39.6NR p=0.010 2 1 Pearson, 2 Log-rank test.

PUNCH01: Interim results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).

Journal of Clinical Oncology Zongren Wang, Bin Huang, Cheng Luo et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.767

767 Background: Our study was established to evaluate the efficacy and safety of IAC combined with tislelizumab and BCG as a bladder-preserving treatment for HR NMIBC pts. Methods: This open-label, single arm phase II study enrolled BCG-naïve HR NMIBC pts with papillary tumors (high-grade Ta or T1 tumors). Firstly, the papillary tumors should be removed all visible lesions by TURBT. Secondly, angiographic catheter was placed into the internal iliac arteries with Seldinger’s percutaneous technique, cisplatin (60 mg/m 2 ) and epirubicin (50 mg/m 2 ) were administered arterially in day 1 (D1), every 3 weeks for 2-4 cycles. And pts received tislelizumab 200 mg ivgtt in D1, every 3 weeks for 2-4 cycles. Finally, pts received 18 instillations of BCG plus at least 8 cycles of tislelizumab (200 mg ivgtt, every 3 weeks). Specifically, pts were started on an induction course of BCG with 6 instillations every week, followed by maintenance with 3 instillations every 2 weeks and 9 instillations every 4 weeks. The primary end point was disease-free survival(DFS) rate at 12 months. Secondary end points were bladder-preservation rate, OS and safety. Our study estimated a DFS rate at 12 months was no less than 55% and the study would enroll 29 pts. Results: By Jul. 2024, 23 eligible pts were enrolled. Twenty-two pts were analyzed (male 90.9%; median age 61 years(37-80); pure TCC 80.0%; median tumor size 3.0 cm (0.4-8.0); multiple papillary tumours=72.7%; high-gradeTa=54.5%, T1=45.5%). Median follow-up was 11.4 months (6.0-40.3), the mean number of IAC cycles was 2.7, mean number of tislelizumab cycles was 8.3, and the median BCG instillations was 10 (6-18). The DFS rate at 12month was 100.0% (95%CI, 63.8%-100%). The bladder-preservation rate at 12 months was 100% (95%CI,100%-100%). The OS rate at 12 months was 100% (95%CI, 100%-100%). 18 pts experienced treatment related adverse events, including nausea (n=6, G2), neutropenia (n=4, G2), fatigue (n=3, G2), increased AST/ALT (n=3,G2), fever (n=2, G3) and myalgia (n=1, G2). Conclusions: Our interim results supported the use of IAC combined with tislelizumab and BCG as a promising bladder-preserving strategy for HR NMIBC pts. Clinical trial information: ChiCTR2200067156 .

Five-year changes in urinary function and prostate volume in patients with localized prostate cancer treated with carbon ion radiotherapy: A prospective study.

Journal of Clinical Oncology Yoshiyuki Miyazawa, Hiroshi Nakayama, Hidemasa Kawamura et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.378

378 Background: The potential of carbon ion radiation therapy (CIRT) as a curative treatment for localized prostate cancer (PCa) has garnered attention due to its characteristic dose distribution. There is no data on long-term urinary function or changes in prostate volume in prostate patients after CIRT. We prospectively collected and analyzed over five years to investigate the outcomes related to the urinary function of localized PCa treated with CIRT. Methods: This study included patients with localized PCa classified as T1-T3N0M0 according to the TNM staging system. A total of 309 patients who underwent carbon-ion radiotherapy (CIRT) between 2010 and 2013 were enrolled. Patients with T1c-T2bN0M0, an initial PSA &lt; 10 ng/ml, and a Gleason score (GS) ≤ 6 were classified as the low-risk group (none androgen deprivation therapy, ADT), while those with ≥T3, an initial PSA ≥ 20 ng/ml, or a GS ≥ 8 were categorized as the high-risk group (neo adjuvant ADT 6 months and adjuvant ADT 1.5 year). The remaining patients were classified into the intermediate-risk group (neo adjuvant ADT 6 months). CIRT was administered 57.6 Gy (RBE) in 16 fractions. Pre- and post-treatment evaluations, including UFM, transrectal ultrasound, and residual urine tests, were performed, with data collected over a 5-year period. This study was approved by the Clinical Ethics Committee of Gunma University Hospital (approval number 693). Results: The median age of the patients was 66.5 years. Analysis of the UFM results showed that the maximum flow rate (mean, ml/s) significantly worsened at 1 month post-treatment (Post) compared to pre-treatment (Pre) but improved to the pre-treatment level by 3 months post-treatment (Pre: 20.0 ± 10.6 ml/s, Post: 14.5 ± 7.3 ml/s, p &lt; 0.05, 3 m: 18.7 ± 8.9 ml/s). The mean flow rate also significantly worsened at 1 month post-treatment compared to pre-treatment but returned to pre-treatment levels at 3 months post-treatment and showed a significant improvement at 3 years post-treatment, which was maintained for up to 5 years (Pre: 8.3 ± 4.0 ml/s, Post: 6.0 ± 3.2 ml/s, p &lt; 0.05, 3 m: 7.7 ± 4.3 ml/s, 3 y: 10.5 ± 4.9 ml/s, p &lt; 0.05). The prostate volume in ADT (-) cases significantly decreased one year after treatment, reaching approximately 80% of the initial volume by three years and remaining stable through five years (1 year: 85.6 ± 18.6%, p &lt; 0.05; 3 years: 78.3 ± 21.9%, p &lt; 0.05). The multivariate analysis identified T classification (T1 vs. ≥T2, p &lt; 0.001) and prostate volume ( p = 0.014) as significant predictive factors for late genitourinary tract complications. Conclusions: The long-term prospective study conducted over five years has elucidated the changes in urinary function and prostate volume in patients with prostate cancer following CIRT. Based on these data, it was suggested that complications in CIRT patients might be predictable through pre-treatment evaluations.

A randomized phase 3 trial of docetaxel added to ADT plus ARTA in patients with metastatic hormone-sensitive prostate cancer (Adding Docetaxel, KCSG- GU22-24).

Journal of Clinical Oncology Kwonoh Park, Inkeun Park, Jae Lyun Lee Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps276

TPS276 Background: The doublet regimen, which adds docetaxel or androgen receptor-targeted agent (ARTA) such as abiraterone, enzalutamide, or apalutamide to androgen deprivation therapy (ADT) has been a standard of care in metastatic hormone-sensitive prostate cancer (mHSPC). A triplet regimen, adding abiraterone or darolutamide to ADT and docetaxel, has also demonstrated efficacy. However, while the benefit of docetaxel in mHSPC has been established in doublet regimen (ADT + docetaxel), the efficacy of adding docetaxel to ADT + ARTA has not been confirmed. Notably, the addition of docetaxel to ADT has shown benefit primarily in patients with high-volume disease. Pivotal trials of triplet regimens were based on administering ADT + docetaxel to all mHSPC patients. However, docetaxel is associated with significant toxicity and a reduction in quality of life, especially among elderly prostate cancer patients. Considering the limited evidence for adding docetaxel to ADT + ARTA and considerable toxicity of docetaxel, this phase 3 study aims to evaluate the effectiveness of adding docetaxel to ADT + ARTA. Methods: This study is a randomized, multicenter, open-label, investigator-initiated phase 3 study. Patients diagnosed with de novo mHSPC and initiated on ADT and ARTA are enrolled and randomized within 16 weeks of starting ADT. Patients are randomized 1:1 to either the Adding-Docetaxel arm or the Non-Docetaxel arm. Randomizations is stratified by ARTA type (abiraterone vs. apalutamide vs. enzalutamide), ECOG PS (0-1 vs. 2), disease volume (high vs. low). The Adding-Docetaxel arm adds 6 cycles of docetaxel 75 mg/m 2 in addition to ADT + ARTA, while the Non-Docetaxel arm receives only ADT + ARTA. The primary endpoint is clinical progression-free survival (cCFS), which defined the time from randomization to progression of soft tissue lesions (per RECIST v1.1), development of cancer pain requiring opioids for more than 7 days, worsening of ECOG PS, need for a change in prostate cancer-specific therapy, need for radiotherapy or surgical treatment, or death. The study is designed to detect a hazard ratio of 0.7 for cPFS, with a significance level of 5%, power of 80%, and an anticipated drop-out rate of 10%. A total of 430 patients (215 per arm) will be enrolled. Patient recruitment began in November 2023. This trial has been registered on the Clinical Research Information Service (http://cris.nih.go.kr) under ID No. KCT0008726 (Release date: August 22, 2023). Clinical trial information: KCT0008726 .

Patient-Reported Outcomes among people living with Chronic Pruritus (PROs-CP): Protocol for a single-center, multistage, mixed-methods prospective cohort study in Thailand

PLoS ONE Surapon Nochaiwong, Chidchanok Ruengorn, Salin Kiratikanon et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0314548

Background Although there have been well-validated patient-reported outcome (PRO) measurements in dermatology practice, there is limited evidence of the adopted comprehensive aspects of PRO measures in long-term follow-up among people living with chronic pruritus. As such, we aim to create a cohort study of the Patient-Reported Outcomes among people living with Chronic Pruritus (PROs-CP) in Thailand. Methods and design This study is a single-center, prospective, open cohort, observational longitudinal study using a multistage, mixed-methods parallel designs to integrate both quantitative and qualitative data regarding PROs among people living with chronic pruritus (itch lasting six or more weeks). The multistage of the PROs-CP study will comprise three sub-studies: (i) study I, PROs measure development, translation, and psychometric validation; (ii) study II, perspectives of people living with chronic pruritus to gain more information regarding disease burden and unmet treatment care responses; and (iii) study III, a longitudinal study to assess the impact of chronic pruritus on long-term health outcomes. Based on a comprehensive review of a panel of stakeholders with chronic skin disease, a set of PRO measurement tools will comprise an established validated Thai version. Meanwhile, meaningful non-Thai versions or unestablished PRO instruments will be translated and developed through this study as appropriate. Quantitative data will be collected based on PRO measures regarding pruritus symptoms and severity, disease activity control and treatment satisfaction, general- and dermatology-specific health-related quality of life, mental health and psychosocial issues, and psychosomatic symptoms. Qualitative data will be obtained from the patient’s perspectives through individual interviews. Ethics and dissemination The study protocol was approved by the Ethics Committee of the Faculty of Medicine, Chiang Mai University (MED-2566-0299), Thailand. Our findings will be disseminated through scientific conferences and publications in peer-reviewed journals. Conclusion Regarding the mixed-methods approach, this open cohort, prospective longitudinal study will provide an evidence-based better understanding of patient perspectives on chronic pruritus burden and inform the utility of a comprehensive set of PROs to measure their long-term health outcomes. Trial registration Thai Clinical Trials Registry (TCTR, thaiclinicaltrials.org) registration TCTR20240327001 (registered on March 27, 2024).

Machine learning prediction of breast cancer local recurrence localization, and distant metastasis after local recurrences

Scientific Reports Kristóf Attila Kovács, Csaba Kerepesi, Dalma Rapcsák et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89339-9

Abstract Local recurrences (LR) can occur within residual breast tissue, chest wall, skin, or newly formed scar tissue. Artificial intelligence (AI) technologies can extract a wide range of tumor features from large datasets helping in oncological decision-making. Recently, machine learning (ML) models have been developed to predict breast cancer recurrence or distant metastasis (DM). However, there is still a lack of models that consider the localization of LR as a tumor feature. To address this gap, here, we analysed data from 154 patients including pathological, clinical, and follow-up data (with an average follow-up of 133.16 months) on both primary tumors (PT) and recurrences. By using ML methods we predicted the localization of LR and the occurrence of DM after LR. The performance (ROC AUC) of the best ML models was 0.75, and 0.69 for predicting LR in breast parenchyma, and surgical scar tissue, respectively, and 0.74 for predicting DM after LR. We identified recurrence localization, and the time elapsed between the detection of primary breast carcinoma and the recurrence, and adjuvant chemotherapy as the most important features associated with further DM. We conclude that combining traditional prognostic factors with ML may provide important tools in the risk assessment of patients with breast LR.

Oncological benefit of avelumab maintenance therapy for advanced or metastatic urothelial carcinoma in comparison with patients with conventional chemotherapy alone era.

Journal of Clinical Oncology Shingo Hatakeyama, Yuya Sekine, Masanao Shinohara et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.711

711 Background: The benefit of avelumab maintenance therapy for advanced or metastatic urothelial carcinoma in real world practice remains unknown. We evaluated the oncological outcomes of avelumab maintenance therapy in comparison with conventional platinum-based 1 st line chemotherapy in real-world practice. Methods: We retrospectively evaluated 302 and 85 patients treated with and conventional platinum-based first-line chemotherapy without avelumab (chemo group) and avelumab maintenance therapy (avelumab group) between March 2004 to Sep 2024. We compared overall survival (OS) between the patients with the chemo and avelumab groups stratified by the number of cycles of first-line chemotherapy. Primary outcome was the comparison of OS in patients without progression disease (non-PD) at cycle 4 between the chemo and avelumab groups. Secondary outcomes were the impact of the administration of pembrolizumab on OS in patients with non-PD at cycle 4 in the chemo group and the comparison of OS in patients with non-PD at cycle 2-3 between the chemo and avelumab groups. Exploratory outcomes were disease-free survival (DFS) and OS based on response rate of first-line chemotherapy, first-line treatment regimen, and number of first-line chemotherapy cycles in the avelumab group. Results: We identified 124 and 49 patients with non-PD at cycle 4 in the chemo and avelumab groups, respectively. The OS from the initiation of first-line chemotherapy in the avelumab group was significantly longer than that in the chemo group (70 vs. 23 months, P = 0.009). We identified 104 and 33 patients with non-PD at cycle 2-3 in the chemo and avelumab groups, respectively. The OS from the initiation of first-line chemotherapy in the avelumab group was significantly longer than that in the chemo group (33 vs. 13 months, P = 0.002). A multivariable Cox regression analysis showed administration of avelumab was significantly associated with reduced risk of OS (hazard ratio, 0.41; P &lt; 0.001). Of 85 patients with avelumab, the median DFS was 17 months from first-line therapy and 8.1 months from the avelumab maintenance therapy, respectively. No significant differences were observed in DFS and OS between first-line treatment regimens, and between the object response rate for first-line chemotherapy. However, the DFS and OS tended to improve in patients with first-line chemotherapy 4 cycles or more. Conclusions: We found a potential benefit of avelumab maintenance therapy on oncological outcome in real-world practice regardless of number of first-line chemotherapy. No progression within first 4 cycles of platinum-based chemotherapy might be one of the key factors for improved outcome. Further long-term follow-up is necessary.

Impact of insurance type on outcomes after radical cystectomy for bladder cancer.

Journal of Clinical Oncology Chirag Doshi, Mazyar Zahir, Anosh Dadabhoy et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.679

679 Background: A patient’s insurance status can significantly impact their access to care, potentially altering their treatment course and outcomes. This study aimed to evaluate the potential influence of different insurance statuses on oncological outcomes, including survival. Methods: We utilized our prospectively maintained IRB-approved radical cystectomy (RC) database (#HS-01B014) to identify all muscle invasive bladder cancer (MIBC) patients who underwent neoadjuvant chemotherapy (NAC) followed by RC from 2000 to 2023. Patients were then categorized based on primary insurance type to Preferred Provider Organizations (PPO), Health Maintenance Organizations (HMO), Medicare, MediCal, and Self-Pay. We extracted demographic, clinical, and oncological outcomes data from our database. All statistical analyses were performed using SAS Version 9.4 (SAS Institute Inc., Cary, NC, USA). Results: A total of 432 patients were included in the final analyses. Patient demographics and baseline characteristics are shown in Table 1. Patients were followed for a median of 42.0 months after cystectomy. On univariate cox regression, PPO insurance was associated with improved OS (Hazards Ratio (HR) = 0.47 [95%CI: 0.29, 0.75], p = .002) and RFS (HR = 0.48 [95%CI: 0.30, 0.78], p = .003) compared to the reference group, Medicare. A multivariate cox regression demonstrated that PPO health plan could enhance OS (HR = 0.49 [95%CI: 0.30, 0.78]) even after adjusting for pathological stage. Having any other health plan had neither a beneficial, nor a detrimental effect on OS or RFS. Conclusions: Better insurance coverage is associated with improved OS and RFS. However, the single institutional design of our study limits the generalizability of our findings. Larger prospective multi-institutional studies are encouraged to better evaluate how insurance status and socioeconomic disparities can affect survival outcomes in MIBC. Demographics and baseline clinical characteristics stratified by insurance status. Variables Medicare (n = 190) HMO (n = 85) PPO (n =143) MediCal (n = 10) Self-pay (n=4) p-value Gender (Male) 148 (77.9%) 69 (81.2%) 117 (81.8%) 8 (80.0%) 3 (75.0%) .917 Age at diagnosis (yrs.) 71.5 ± 6.4 64.6 ± 10.0 60.2 ± 8.6 55.7 ± 12.9 54.8 ± 14.6 &lt;.001 Charlson Comorbidity Index 0 30 (15.8%) 26 (30.6%) 55 (38.4%) 3 (30.0%) 1 (25.0%) &lt;.001 1 52 (27.4%) 16 (18.8%) 35 (24.5%) 4 (40.0%) 2 (50.0%) ≥ 2 108 (56.8%) 43 (50.6%) 53 (37.1%) 3 (30.0%) 1 (25.0%) Pathological staging &lt; (y)pT2; pN0 115 (60.5%) 59 (69.4%) 94 (65.7%) 4 (40.0%) 2 (50.0%) .515 &gt; (y)pT2; pN0 34 (17.9%) 9 (10.6%) 25 (17.5%) 2 (20.0%) 1 (25.0%) pN+ 41 (21.6%) 17 (20.0%) 24 (16.8%) 4 (40.0%) 1 (25.0%) Income percentiles 0 - 40th 20 (10.5%) 13 (15.3%) 14 (9.8%) 4 (40.0%) 0 (0.0%) .193 40 - 60th 56 (29.5%) 26 (30.6%) 39 (27.3%) 4 (40.0%) 1 (25.0%) 60 - 80th 76 (40.0%) 33 (38.8%) 58 (40.6%) 2 (20.0%) 2 (50.0%) 80 - 100th 38 (20.0%) 13 (15.3%) 32 (22.4%) 0 (0.0%) 2 (50.0%)

Evaluating the association between bone pain and radiologic progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC).

Journal of Clinical Oncology Deniz Tural, Caner Kapar, Selçuk Şahin et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.94

94 Background: Previous studies have shown bone pain to be associated with worse survival in patients with metastatic castration-resistant prostate cancer (mCRPC). However, there are few data regarding bone pain and survival outcomes in patients with (mCSPC). In the current study, we evaluated the association between bone pain and rPFS in patients treated with mCSPC. Methods: rPFS were estimated by using the Kaplan-Meier method and the log-rank test was used for the comparison between different subgroups. Differences in baseline characteristics by bone pain status at mHSPC were evaluated with χ2 test for categorical variables. Results: Data from 205 patients were analyzed. A detail of the patient’s characteristics is shown (Table).The median rPFS for all populations was calculated as 24 mo. In univariate analysis, the median rPFS were 17 vs 29.5 mo in patients with bone pain presentations vs none-pain (p=0.001), 29 vs 20 mo in patients with ECOG PS 0 or 1≥ (p=0.09), 22 vs 14 mo in patients with DNA repair mutations absent and present(p=0.06), 27 mo vs 19 mo in patients with low volume presentation vs high volume (p=0.05), 15 vs 25 months in patients with or without liver metastases (p=0.003), 17 mo vs 27 mo in patients with hemoglobin levels &lt;12 gr/dL or higher (p=0.002), respectively. In multivariate analysis, bone pain (HR 1.9; 95% CI 1.2-3.1; p:0.001), hemoglobin&lt;12 gr/dL (HR 2; 95% CI 1.9 -3.1; p:0.005) were found to be an independent determinant of short rPFS. Conclusions: Bone pain is associated with short rPFS in mCSPC. The current study showed bone pain needs to be selected in the treatment choice or prognostic model in mCSPC. Baseline characteristics of patients. Variable Patients Presence of bone pain Absence of bone pain (n=104) (n=101) p value ECOG performance status, n(%), p 0 ≥1 34 (%32.7)70 (%67.3) 67 (%66.3)34 (%33.7) &lt;0,001 Gleason score at diagnosis, n(%), p &lt;8 ≥8 Unknown 31 (%29.8)66 (%63.5)7 (%6.7) 34 (%33.7)65 (%64.4)2 (%1.9) 0,723 Under/over 70 years old, n(%), p &lt;70 years ≥70 years 40 (%38.5)64 (%61.5) 47 (%46.5)54 (%53.5) 0,242 High/low volume disease, n(%), p High volume Low volume 76 (%73.1)28 (%26.9) 29 (%28.7)72 (%71.3) &lt;0,001 Metastasis at diagnosis, n(%), p Yes No 79 (%76)25 (%24) 64 (%63.4)37 (%36.6) 0,050 Metachronous metastasis, n(%), p Yes No 25 (%24)79 (%76) 36 (%35.6)65 (%64.4) 0,069 Liver metastasis at diagnosis, n(%), p Yes No 9 (%8.7)95 (%91.3) 0 (%0)101 (%100) 0,002 DNA repair mutation, n(%), p Positive Negative Unknown 10 (%9.6)38 (%36.5)56 (%53.9) 5 (%5)38 (%37.6)58 (%57.4) 0,436 Hemoglobin levels, n(%), p &lt;12 gr/dL ≥12 gr/dL Unknown 30 (%28.8)61 (%58.7)13 (%12.5) 20 (%19.8)74 (%73.3)7 (%6.9) 0,073 PSA levels, n(%), p &lt;17 ng/ml ≥17 ng/ml 46 (%44.2)58 (%55.8) 56 (%55.4)45 (%44.6) 0,094 First line treatment 0.08 Androgen receptor pathway inhibitor 43 (%41.3) 45 (%44.6) Only ADT 34 (%32.7) 42 (%41.6) Docetaxel 27 (%26) 14 (%13.8)

Treatment patterns of MIBC patients not receiving radical cystectomy: Results from a real-world survey in Europe.

Journal of Clinical Oncology Anthony Eccleston, Abin Koshy, Julia Brinkmann et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.738

738 Background: Neoadjuvant chemotherapy followed by Radical cystectomy (RC) is the current standard of care for muscle invasive bladder cancer (MIBC). RC is associated with significant risks and quality of life (QoL) implications. This real-world survey aimed to understand the drivers behind why patients (pts) do not receive RC, and alternative treatments initiated with curative intent. Methods: Medical oncologists and urologists across France, Germany, Italy, Spain, and the UK were recruited to the Adelphi MIBC Disease Specific Programme (DSP)™ to extract patient medical records for their next 4 consecutive pts with MIBC who did not receive RC. Data was collected Dec 2023 to May 2024. Results: 200 physicians provided data for 762 pts with MIBC who didn’t receive RC, of whom 388 (51%) refused RC; 357 (47%) were ineligible for RC; and 17 (2%) didn’t receive RC for other reasons. The mean (standard deviation) age of pts was 73.9 (9.3) years; 70.1 (9.2) for pts that refused RC and 78.2 (7.4) for RC ineligible pts. 78% of pts were diagnosed de novo MIBC, and 20% of pts progressed from non-invasive disease. When surveyed as to why their pts may refuse RC, the most common reason physicians reported was pts not wanting a stoma (80%), followed by QoL concerns (66%) and concerns with the risk of surgery (48%). When asked which factors they consider when determining a patient’s eligibility for RC, the most common were comorbidities (90%), physical performance status (87%), and cardiac status (68%). Of the 388 pts that refused RC, the top 3 reasons provided by patients for refusal were QoL concerns following RC (71%), not wanting to live with a stoma (59%), and concerns over the risk of surgery (37%). Amongst the 357 RC ineligible pts the most common reasons they were deemed as such were their comorbidities (40%), physical performance status (37%), and cardiac status (11%). Bladder sparing therapy with curative intent (BSTx) was received by 367 (48%) of non-RC pts, of whom 94% had only 1 line. Treatments received at 1 st line can be seen below. Alongside BSTx non-radical surgery was received by 78% of pts, most commonly transurethral resection (74%) or partial cystectomy (5%). Complete response to 1 st line BSTx was reported by physicians in 44% of pts. Among pts that refused RC 48% recorded a complete response whilst this was 36% for RC ineligible pts. Conclusions: In this analysis, a similar proportion of pts refuse RC as are considered ineligible. There is a need for novel approaches to improve the options available to pts without compromising outcomes. Treatments received at 1 st line BSTx n, (%). All non-RC ptsn=762 Refused RCn=388 RC ineligiblen=357 No RC - other reasonn=17 Chemotherapy only 151 (20) 90 (23) 59 (17) 2 (12) Radiotherapy only 52 (7) 19 (5) 32 (9) 1 (6) Chemoradiotherapy 134 (18) 97 (25) 35 (10) 2 (12) Treatments including immunotherapies 21 (3) 11 (3) 10 (3) 0 (0) Other treatments 9 (1) 6 (2) 3 (1) 0 (0) No BSTx 395 (52) 165 (43) 218 (61) 12 (71)

Development of a functional electrical stimulation cycling toolkit for spinal cord injury rehabilitation in acute care hospitals: A participatory action approach

PLoS ONE Hope Jervis-Rademeyer, Srijana Gautam, Stephanie Cornell et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0316296

The purpose of our study was to develop a toolkit to facilitate the implementation of functional electrical stimulation (FES) cycling for persons with a newly acquired spinal cord injury (SCI) in the acute care inpatient hospital setting. The researchers and community members used participatory action as a research approach to co-create the toolkit. We held two focus groups to develop drafts, with a third meeting to provide feedback, and a fourth meeting to evaluate the toolkit and determine dissemination strategies. Toolkit development followed the Planning, Action, Reflection, Evaluation cycle. We used an iterative design informed by focus group and toolkit consultant (SC) feedback. In focus group discussions, we included FES cycling champions (JK, DW) who led acute care implementation. Focus group members, recruited through purposive sampling, had to 1) have an understanding about FES cycling in acute care for SCI and 2) represent one of these groups: individual living with SCI, social support, hospital manager, clinician, therapist, researcher, and/or acute care FES cycling champion. Twelve individuals took part in four focus groups to develop a toolkit designed to facilitate implementation of FES cycling in SCI acute care in Edmonton, Alberta. Group members included an individual with lived experience, three acute-care occupational or physical therapists, three acute-care hospital managers, and five researchers. Two physical therapists also identified as clinical FES cycling champions. Following an inductive content analysis, we identified four main themes: 1) Health care provider toolkit content and categories, 2) Health care provider toolkit end product, 3) Collaborations between groups and institutions and 4) Infrastructure. Interested parties who utilize FES cycling in acute care for SCI rehabilitation agree that toolkits should target the appropriate group, be acute care setting-specific, and provide information for a smooth transition in care.

The long-term associations of childhood parental loss with attachment, creativity, and epigenetic regulation

Scientific Reports Adi Shapira Dvilansky, Hodaya Zadok, Anat Shoshani et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89467-2

Downregulation of E-selectin and contributions to immune restraining in prostate cancer.

Journal of Clinical Oncology Ida Deichaite, Andrew Elliott, Ahmed Shabaik et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.257

257 Background: Immune surveillance in prostate cancer (PCa) relies on leukocyte trafficking into target tissues, a process mediated by endothelial adhesion molecules. This study investigates the role of E-selectin (SELE) in PCa immune evasion and patient outcomes. Methods: We analyzed transcriptomic data from 7,523 PCa samples (4,768 localized; 2,755 metastatic) molecularly profiled at Caris Life Sciences to assess SELE expression. Correlations between TNF and adhesion molecule expression were examined in normal prostate and PCa tissues. Survival analysis was performed based on SELE expression levels. Immunohistochemistry was conducted to evaluate SELE protein expression in tumor, benign prostatic hyperplasia (BPH), and stromal samples. Results: SELE was significantly upregulated in localized PCa samples compared to metastases (SELE: 0.83 vs 0.47 TPM, p&lt;0.001), along with SELP (P-selectin) (3.15 vs 1.29 TPM, p&lt;0.0001), ICAM1 (5.05 vs 3.70, P&lt;0.0001) and VCAM1 (7.10 vs 5.41, P&lt;0.001), while TNF expression was similar (0.48 vs 0.43 TPM, P&lt;0.001). TNF positively correlated with SELE, with a stronger correlation observed in metastatic vs localized PCa samples, suggesting altered transcriptional regulation. High expression of SELE was associated with improved survival among patients with localized PCa (HR=0.61, p&lt;0.0001), with no significant difference observed among those with metastatic PCa (HR=0.90, p=0.153). Among those with localized PCa, high expression of SELP was also associated with improved survival (HR=0.75, p&lt;0.001), while worse overall survival was associated with high expression of ICAM1 (HR=1.58, p&lt;0.0001), VCAM1 (HR=1.73, p&lt;0.0001), and TNF (HR=1.23, p=0.004). Combined high SELE/low TNF demonstrated an enhanced survival effect compared to low SELE/high TNF (HR=0.44, p&lt;0.001). Conclusions: Our findings suggest that downregulation of SELE in PCa contributes to tumor "coldness" by potentially reducing anti-tumor immune cell infiltration. This mechanism may explain the limited efficacy of immune checkpoint inhibitors in PCa. The strong association between SELE expression and improved survival highlights their potential for prognostic biomarker and therapeutic target in PCa.

Prognostic and predictive genomic biomarkers in metastatic clear cell renal cell carcinoma (mccRCC): A large retrospective analysis of real-world data from a US-based clinico-genomic database (CGDB).

Journal of Clinical Oncology Mimma Rizzo, Gaetano Pezzicoli, Camilla Porta et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.473

473 Background: The absence of validated prognostic and predictive biomarkers constitutes a significant barrier to appropriate selection among immune checkpoint inhibitor combinations (ICI-C) for individual patients (pts) with mccRCC. Our study aimed to evaluate the prognostic and predictive value of single-gene alterations (GAs) and gene clusters in a large real-world case series of mccRCC. Methods: This study employed data from the US-based de-identified Flatiron Health-Foundation Medicine Inc. (FH-FMI) CGDB, comprising 858 mccRCC pts diagnosed between 2011 and 2022 in 280 US cancer clinics. The presence of GAs was determined using Foundation Medicine tests on tumor tissue specimens. The co-occurrence and mutual exclusivity of the most common GAs were assessed utilizing Fisher's exact test. The Louvain algorithm was applied to identify three co-occurring gene clusters (C) on the gene network graph: C1: VHL , SETD2 , PBRM1 , KDM5C , NFE2L2; C2: TP53 , TSC1 , TERT , DNMT3A ; C3: CDKN2A , CDKN2B , BAP1 , NF2 , MTAP . Pts were labelled as C+ if they had one or more mutations within a specific cluster and none in the others. Cox proportional hazard model was used to discern the prognostic and predictive value of GAs. Median overall survival (mOS) and progression-free survival (mPFS) were estimated using the Kaplan-Meier method. Results: The prognostic analysis encompassed 782 pts with mccRCC, while the predictive analysis involved 493 pts profiled with FMI genomic tests within 3 months of starting first-line systemic therapy (1L). GAs of seven genes ( CDKN2A , CDKN2B , TP53 , PTEN , NF2 , PIK3CA , MTAP ) correlated with a poorer prognosis, whereas PBRM1 mutants exhibited a favorable OS. C1+ pts had higher OS compared to C1- (mOS: 40 vs. 19 months; HR: 0.63, p &lt;0.001), while C3+ was associated with worse OS (mOS: 18 vs. 27 months; HR: 1.36, p = 0.023). In 1L, 201 pts (40.8%) received antiangiogenic monotherapy (AAm) (mPFS: 7.0 months) and 172 pts (34.9%) received ICI-C (16.4% ICI+ICI, 18.5% ICI+AA) (mPFS: 6.8 months). 170 (34.5%), 43 (8.7%), and 71 (14.4%) pts were categorized as C1+, C2+, and C3+, respectively. TERT , TSC1 , and TET2 alterations were positive predictors of 1L-PFS for ICI-C vs. AAm (HR=0.44, 0.23, 0.20; p&lt;0.05). C1+ favored AAm over ICI-C (HR=2.30, p=0.01) while C2+ favored ICI-C over AAm (HR=0.39, p=0.039). Among ICI-C, ICI+AA was more effective than ICI+ICI in pts with SETD2 alterations (HR=0.38, 0.020), and less effective in mutant TSC1 (HR=8.60, p=0.013). Conclusions: This study highlights the prognostic value of 8 GAs and 2 clusters of co-occurring GAs, and identifies 3 GAs and 1 cluster of co-occurring GAs to be positive predictors of 1L-PFS for ICI-C in a large mccRCC population. Prospective validation is required to confirm the prognostic and predictive role of these GAs and to tailor therapeutic strategies.

Treatment sequence (TS) and overall survival (OS) in patients with metastatic urothelial cancer (mUC): An observational, multicenter, real-life STATES-Bladder study.

Journal of Clinical Oncology Fabien Moinard-Butot, Jean-Baptiste Barbe-Richaud, Edwige Baudry et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.724

724 Background: mUC remains of poor prognosis despite standard first-line platinum-based chemotherapy (PBC), maintenance avelumab for ptd non progressing PBC. Enfortumab vedotin (EV) and erdafitinib offers a promising option in later lines of therapy. However all patients will not receive the whole sequence and the attrition rate remains crucial. As the therapeutic landscape evolved over the last 5 years no recent data are available on an whole mUC population including responder and non responder to PBC. This study aims to evaluate OS and treatment outcomes in real-world practice across multiple centers in France. Methods: This retrospective study included 180 patients with mUC treated with first-line PBC between January 2020 and December 2023. The primary objective was to assess OS in the overall population. Secondary objectives included OS by treatment sequence, performance status (PS), and attrition rates across treatment lines. We analyzed OS in patients receiving maintenance avelumab, those progressing to second-line therapies, and attrition at each treatment line. Additionally, OS was compared between patients with WHO PS 0-1 and WHO PS 2-3. Results: The median age was 72 years (41-91), with 81% male. Synchronous metastases were observed in 52% of patients, while 48% had metachronous metastases. The most common metastatic sites were lymph nodes (68%), lung (33%), bone (32%) and liver (21%). 44% of patients received cisplatin-based chemotherapy, while 56% were treated with carboplatin. Among patients with WHO PS 2-3 (20%), median age was 73 years (41-91), with a greater proportion having liver (25%) and bone (42%) metastases. For the entire population, median OS was 22.4 months [CI95%,17.2-26.7]. Patients receiving avelumab maintenance had a median OS of 29.0 months [CI95%,22.5-NA], while those progressing to second-line therapy showed a median OS of 15.6 months [CI95%,12.4-24.4]. Median OS for patients treated with EV at any treatment line was 26.1 months [CI95%,22.5-NA]. 58% of patients received avelumab maintenance. Attrition rates were 57% after first-line, 37% after second-line, and 9% after third-line therapy. Patients with WHO PS 0-1 had a significantly better median OS of 26.4 months [CI95%,22.5-NA], compared to 7.2 months [CI95%,6.1-13.1] for those with WHO PS 2-3 (p&lt;0.001). Conclusions: These real-world survival outcomes are consistent with large phase 3 trials. The particularly poor prognosis of patients with WHO PS 2-3 underscores the need for innovative treatment strategies, such as EV plus pembrolizumab, as highlighted by the EV-302 study, to potentially improve outcomes in this challenging subgroup.